sb 216763 and ketamine
sb 216763 has been researched along with ketamine in 4 studies
Compound Research Comparison
| Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) | Studies (ketamine) | Trials (ketamine) | Recent Studies (post-2010) (ketamine) |
|---|---|---|---|---|---|
| 342 | 0 | 225 | 15,029 | 2,321 | 6,678 |
Protein Interaction Comparison
| Protein | Taxonomy | sb 216763 (IC50) | ketamine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 4.216 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 4.216 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 3.7762 | |
| Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 3.5563 | |
| Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 4.1059 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 5.02 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 5.02 |
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chan, MH; Chen, HH; Chiu, PH; Lin, CY | 1 |
| Dang, YH; Gao, CG; Hashimoto, K; Jia, M; Ma, R; Ma, XC; Wang, F; Wu, J | 1 |
| Aghajanian, GK; Duman, RS; Dwyer, JM; Fuchikami, M; Lepack, AE; Liu, RJ | 1 |
| Beveridge, TJ; Huang, K; Huang, X; Li, P; Li, X; Liu, Y; Yang, S; Zheng, W; Zhou, W | 1 |
Other Studies
4 other study(ies) available for sb 216763 and ketamine
| Article | Year |
|---|---|
Inhibition of glycogen synthase kinase-3 attenuates psychotomimetic effects of ketamine.
Topics: Acoustic Stimulation; Analysis of Variance; Animals; Behavior, Animal; Behavioral Symptoms; Brain; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Glycogen Synthase Kinase 3; Indoles; Inhibition, Psychological; Injections, Intraventricular; Ketamine; Male; Maleimides; Mice; Mice, Inbred ICR; Motor Activity; Oxathiins; Psychoacoustics; Recognition, Psychology; Reflex, Startle | 2012 |
Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder; Disease Models, Animal; Enzyme Inhibitors; Glycogen Synthase Kinase 3; Hindlimb Suspension; Humans; Indoles; Ketamine; Male; Maleimides; Mice; Motor Activity; Stress, Physiological; Sucrose | 2013 |
GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine.
Topics: Animals; Antidepressive Agents; Dendritic Spines; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Postsynaptic Potentials; Glycogen Synthase Kinase 3; Immobility Response, Tonic; Indoles; Ketamine; Lithium Chloride; Male; Maleimides; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Phosphorylation; Prefrontal Cortex; Rats; Signal Transduction; Synapses; TOR Serine-Threonine Kinases | 2013 |
The effects of GSK-3β blockade on ketamine self-administration and relapse to drug-seeking behavior in rats.
Topics: Animals; Drug-Seeking Behavior; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Indoles; Ketamine; Lithium Chloride; Male; Maleimides; Neostriatum; Nucleus Accumbens; Phosphorylation; Rats; Recurrence; Reinforcement Schedule; Self Administration; Ventral Tegmental Area | 2015 |